Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?

Medicine (Baltimore). 2011 May;90(3):168-170. doi: 10.1097/MD.0b013e31821a2f07.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / ethnology
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Erlotinib Hydrochloride
  • Gefitinib
  • Genes, erbB-1 / genetics*
  • Genetic Testing
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / ethnology
  • Lung Neoplasms / genetics
  • Mutation / genetics*
  • Pharmacogenetics
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Quinazolines / therapeutic use
  • Taiwan
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Erlotinib Hydrochloride
  • Protein-Tyrosine Kinases
  • Gefitinib